PRE 14A

PROXY STATEMENT

Company: RELMADA THERAPEUTICS, INC.
Filed: March 31, 2022
Period of Report: March 31, 2022
Accession Number: 0001213900-22-016753

View Document ↗ View on SEC.gov ↗